Skip to content

A Comparative Study Between High-Dose Cisatracurium And Rocuronium In Rapid Sequence Intubation: Randomized Controlled Trial

A Comparative Study Between High-Dose Cisatracurium And Rocuronium In Rapid Sequence Intubation: Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210824007
Enrollment
124
Registered
2021-08-24
Start date
2021-08-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A patient who required general anesthesia for any kind of surgery General anesthesia Rapid sequence intubation

Interventions

Using intravenous rocuronium 1.2 mg/kg in rapid sequence intubation,Using intravenous cisatracurium 0.4 mg/kg in rapid sequence intubation
Active Comparator Drug,Experimental Drug
Rocuronium,Cisatracurium

Sponsors

Faculty of Medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18-65 years old adult patients who are willing to join the research, 2. Patients undergoing more than 1 hour of elective surgery requiring general anesthesia, 3. Patients who skipped heavy meals for more than 8 hours, light meals for more than 6 hours, and clear liquids for more than 2 hours before undergoing anesthesia, 4. Patients with American Society of Anesthesiologists Physical Status (ASA PS) classification I-III

Exclusion criteria

Exclusion criteria: 1. Patients refuse to participate in the research or request to withdraw, 2. Patients with a history of drug allergy related to the research, 3. Patients who are pregnant or breastfeeding, 4. Patients who are predicted difficult intubation, 5. Patients at high risk of aspiration, 6. Patients with a history of asthma or reactive airway disease were treated with medication at the time of the study, 7. Patients with severe diseases such as cardiovascular disease, neuromuscular disease, impaired hepatic and renal function, 8. Patients who have a cardiac pacemaker, 9. Patients with a history of using medication that affect the action of muscle relaxants such as aminoglycoside, antidepressants, anticonvulsants, antiarrhythmic (calcium channel blockers or quinidine), and magnesium sulfate

Design outcomes

Primary

MeasureTime frame
Intubating condition 90 seconds after neuromuscular blocking agent administration Intubating condition scale

Secondary

MeasureTime frame
Anesthesiologist satisfraction After successful intubation Numeric rating scale,Train of four at 90 sec 90 seconds after neuromuscular blocking agent administration Train of four monitoring,Train of four at successful intubation At successful intubation Train of four monitoring,Time to TOF 0 During general anesthesia Train of four monitoring,Time to TOF 1 During general anesthesia Train of four monitoring,Skin manifestation During general anesthesia Number of events,Hypotension During general anesthesia Number of events required treatment,Hypertension During general anesthesia Number of events required treatment,Tachycardia During general anesthesia Number of events required treatment,Bradycardia During general anesthesia Number of events required treatment

Countries

Thailand

Contacts

Public ContactNapanont Kiatmongkolkul

Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University

napanont.kia@mahidol.edu0816234477

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026